{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:37:11Z","timestamp":1792643831823,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Burns"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.burns.2009.06.213","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T08:14:02Z","timestamp":1253607242000},"page":"152-163","source":"Crossref","is-referenced-by-count":99,"title":["Toxic epidermal necrolysis (Lyell's disease)"],"prefix":"10.1016","volume":"36","author":[{"given":"Mario","family":"Lissia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.burns.2009.06.213_bib1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archpedi.1922.04120120077005","article-title":"A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children","volume":"24","author":"Stevens","year":"1922","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.burns.2009.06.213_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib3","series-title":"Fitzpatrick's dermatology in general medicine","year":"2003"},{"key":"10.1016\/j.burns.2009.06.213_bib4","first-page":"1","article-title":"Bullous-skin eruptions following sulfonamide administration: relationship to bullous erythema multiforme","volume":"3","author":"Thomas","year":"1948","journal-title":"J Am Med Womens Assoc"},{"key":"10.1016\/j.burns.2009.06.213_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cden.2004.08.003","article-title":"Erythema multiforme: a review and contrast from Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"49","author":"Williams","year":"2005","journal-title":"Dent Clin North Am"},{"key":"10.1016\/j.burns.2009.06.213_bib6","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a clinical classification","volume":"102","author":"Roujeau","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0001-7310(06)73376-2","article-title":"Sindrome de Stevens\u2013Johnson y necrolisis epidermica toxica: experiencia clinica y revision de la literatura especializada","volume":"97","author":"Laguna","year":"2006","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.burns.2009.06.213_bib8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1081-1206(10)60789-2","article-title":"Pathogenesis and recent therapeutic trends in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"97","author":"Khalili","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.burns.2009.06.213_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.burns.2009.06.213_bib10","first-page":"1883","article-title":"Erythema multiforme","volume":"74","author":"Lamoreux","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.burns.2009.06.213_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.131.5.539","article-title":"Erythema multiforme with mucous membrane involvement and Stevens\u2013Johnson syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.126.1.43","article-title":"The incidence of erythema multiforme, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.sder.2006.04.004","article-title":"Toxic epidermal necrolysis and intravenous immunoglobulin: a review","volume":"25","author":"Trent","year":"2006","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.burns.2009.06.213_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.126.1.37","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981\u20131985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archderm.127.6.831","article-title":"A population-based study of Stevens\u2013Johnson syndrome. Incidence and antecedent drug exposures","volume":"127","author":"Strom","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb03598.x","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens\u2013Johnson syndrome: our current understanding","volume":"6","author":"French","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.burns.2009.06.213_bib19","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.burns.2009.06.213_bib20","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/00006534-200209010-00008","article-title":"Outcome of patients with toxic epidermal necrolysis syndrome revisited","volume":"110","author":"Ducic","year":"2002","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.burns.2009.06.213_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib22","first-page":"123","article-title":"Toxic epidermal necrolysis","volume":"59","author":"Schwartz","year":"1997","journal-title":"Cutis"},{"key":"10.1016\/j.burns.2009.06.213_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-200326020-00004","article-title":"Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions","volume":"26","author":"Leone","year":"2003","journal-title":"Drug Safe"},{"key":"10.1016\/j.burns.2009.06.213_bib24","series-title":"Litt's drug eruption reference manual","year":"2005"},{"key":"10.1016\/j.burns.2009.06.213_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Borchers","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.burns.2009.06.213_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study","volume":"128","author":"Mockenhaupt","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib28","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1346-8138.1997.tb02308.x","article-title":"Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"24","author":"Takeda","year":"1997","journal-title":"J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1365-2230.1999.00473.x","article-title":"Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma","volume":"24","author":"Stone","year":"1999","journal-title":"Clin Exp Dermatol (Print)"},{"key":"10.1016\/j.burns.2009.06.213_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archderm.110.1.103","article-title":"Fumigant-induced toxic epidermal necrolysis","volume":"110","author":"Radimer","year":"1974","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00043764-199202000-00012","article-title":"Work-related toxic epidermal necrolysis?","volume":"34","author":"House","year":"1992","journal-title":"J Occup Med"},{"key":"10.1016\/j.burns.2009.06.213_bib32","first-page":"1446","article-title":"Une complication rare de la vaccination jennerienne. Le necrolyse epidermique","volume":"101","author":"Martine","year":"1971","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.burns.2009.06.213_bib33","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archderm.110.5.766","article-title":"Toxic epidermal necrolysis following measles vaccination","volume":"110","author":"Shoss","year":"1974","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0190-9622(91)70176-3","article-title":"Toxic epidermal necrolysis: a review","volume":"25","author":"Avakian","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/archderm.1962.01590110074011","article-title":"Toxic epidermal necrolysis","volume":"86","author":"Beare","year":"1962","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1468-3083.1999.tb00846.x","article-title":"Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination","volume":"13","author":"Dobrosavljevic","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.burns.2009.06.213_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/adc.53.1.38","article-title":"Mycoplasma pneumoniae infections in children","volume":"53","author":"Stevens","year":"1978","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.burns.2009.06.213_bib38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02113442","article-title":"Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection","volume":"14","author":"Fournier","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis (Print)"},{"key":"10.1016\/j.burns.2009.06.213_bib39","first-page":"366","article-title":"Clinical characteristics of childhood erythema multiforme, Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Taiwanese children","volume":"37","author":"Lam","year":"2004","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.burns.2009.06.213_bib40","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.burns.2009.06.213_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.burns.2009.06.213_bib42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000372-200010000-00005","article-title":"Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis","volume":"22","author":"Paquet","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.burns.2009.06.213_bib43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.129.4.466","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib44","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib45","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.burns.2009.06.213_bib46","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archderm.130.5.598","article-title":"Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine","volume":"130","author":"Friedmann","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00403-005-0607-3","article-title":"Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis","volume":"297","author":"Paquet","year":"2005","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.burns.2009.06.213_bib48","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1034\/j.1398-9995.2000.00628.x","article-title":"Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions","volume":"55","author":"Blanca","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.burns.2009.06.213_bib49","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","article-title":"Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption","volume":"62","author":"Kano","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.burns.2009.06.213_bib50","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.130.5.605","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors","volume":"119","author":"Le Cleach","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.burns.2009.06.213_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2005.07023.x","article-title":"The CD40\/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"154","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0625.1995.tb00211.x","article-title":"Low N-acetylating capacity in patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"4","author":"Dietrich","year":"1995","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2332\/allergolint.55.27","article-title":"Immune mechanisms in drug allergy","volume":"55","author":"Roujeau","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.burns.2009.06.213_bib55","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.burns.2009.06.213_bib56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","article-title":"Human leukocyte antigens and drug hypersensitivity","volume":"7","author":"Chung","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.burns.2009.06.213_bib57","series-title":"Kuby immunology","author":"Kindt","year":"2006"},{"key":"10.1016\/j.burns.2009.06.213_bib58","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib59","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.burns.2009.06.213_bib60","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4049\/jimmunol.170.2.677","article-title":"Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand","volume":"170","author":"Knox","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.burns.2009.06.213_bib61","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib62","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.burns.2009.06.213_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.burns.2009.06.213_bib64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/bcmd.2002.0555","article-title":"Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs","volume":"29","author":"Posadas","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.burns.2009.06.213_bib65","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib66","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.4049\/jimmunol.162.12.7140","article-title":"Crosstalk between keratinocytes and T lymphocytes via Fas\/Fas ligand interaction: modulation by cytokines","volume":"162","author":"Arnold","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.burns.2009.06.213_bib67","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib68","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.burns.2009.06.213_bib69","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.123.9.1160","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib70","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1346-8138.1998.tb02450.x","article-title":"Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium","volume":"25","author":"Sugimoto","year":"1998","journal-title":"J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1440-0960.1999.00342.x","article-title":"Clinical manifestations and outcomes in 17 cases of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"40","author":"Wong","year":"1999","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1524-4725.2003.29025.x","article-title":"Treatment of toxic epidermal necrolysis with moisture-retentive ointment: a case report and review of the literature","volume":"29","author":"Atiyeh","year":"2003","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.burns.2009.06.213_bib73","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00004630-200021030-00010","article-title":"Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis","volume":"21","author":"Mofid","year":"2000","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2009.06.213_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000070938","article-title":"Dermatological and ophthalmological sequels in toxic epidermal necrolysis","volume":"207","author":"Magina","year":"2003","journal-title":"Dermatology (Basel)"},{"key":"10.1016\/j.burns.2009.06.213_bib75","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(85)92146-4","article-title":"Sj\u00f6gren-like syndrome after drug-induced toxic epidermal necrolysis","volume":"1","author":"Roujeau","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.burns.2009.06.213_bib76","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ophtha.2004.11.035","article-title":"Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis syndrome","volume":"112","author":"Di Pascuale","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.burns.2009.06.213_bib77","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.BCR.0000150215.78220.79","article-title":"Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center","volume":"26","author":"Haber","year":"2005","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2009.06.213_bib78","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/archdermatol.2009.540","article-title":"Risk factors for the development of ocular complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"145","author":"Gueudry","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib79","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.tripleo.2007.12.023","article-title":"Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention","volume":"105","author":"Sedghizadeh","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.burns.2009.06.213_bib80","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.burns.2009.06.213_bib81","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0305-4179(95)00140-9","article-title":"Toxic epidermal necrolysis in a burns centre: a 6-year review","volume":"22","author":"Khoo","year":"1996","journal-title":"Burns"},{"key":"10.1016\/j.burns.2009.06.213_bib82","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00004630-199601000-00008","article-title":"Experience with toxic epidermal necrolysis treated in a burn center","volume":"17","author":"Yarbrough","year":"1996","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2009.06.213_bib83","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809040-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.burns.2009.06.213_bib84","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2009.06.213_bib85","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1365-4632.2007.03277.x","article-title":"Practical guidelines for the management of toxic epidermal necrolysis and Stevens\u2013Johnson syndrome","volume":"46","author":"Fromowitz","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib86","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-277X.2006.00685.x","article-title":"Nutrition of toxic epidermal necrolysis","volume":"19","author":"Gravante","year":"2006","journal-title":"J Hum Nutr Diet"},{"key":"10.1016\/j.burns.2009.06.213_bib87","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/011542659701200281","article-title":"Nutrition requirements in patients with toxic epidermal necrolysis","volume":"12","author":"Coss-Bu","year":"1997","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.burns.2009.06.213_bib88","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-277X.2005.00624.x","article-title":"Immune modulating nutrition support for a patient with severe toxic epidermal necrolysis","volume":"18","author":"Windle","year":"2005","journal-title":"J Hum Nutr Diet"},{"key":"10.1016\/j.burns.2009.06.213_bib89","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A 10-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2009.06.213_bib90","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib91","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0305-4179(00)00136-4","article-title":"Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong","volume":"27","author":"Ying","year":"2001","journal-title":"Burns"},{"key":"10.1016\/j.burns.2009.06.213_bib92","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1526-0968.2002.00409.x","article-title":"Plasma exchange in patients with toxic epidermal necrolysis","volume":"6","author":"Bamichas","year":"2002","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.burns.2009.06.213_bib93","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/milmed\/167.8.701","article-title":"A case report and a proposed algorithm for the transfer of patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis to a burn center","volume":"167","author":"Ellis","year":"2002","journal-title":"Mil Med"},{"key":"10.1016\/j.burns.2009.06.213_bib94","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1525-1470.2008.00766.x","article-title":"Use of Suprathel\u00ae dressing in a young infant with TEN","volume":"25","author":"Pfurtscheller","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib95","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-4362.1992.tb04238.x","article-title":"Toxic epidermal necrolysis","volume":"31","author":"Parsons","year":"1992","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib96","first-page":"1865","article-title":"Serious and life-threatening drug eruptions","volume":"51","author":"Manders","year":"1995","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.burns.2009.06.213_bib97","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0305-4179(02)00075-X","article-title":"Benefit\u2013cost analysis of moist exposed burn ointment","volume":"28","author":"Atiyeh","year":"2002","journal-title":"Burns"},{"key":"10.1016\/j.burns.2009.06.213_bib98","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00004630-199505000-00020","article-title":"Use of Biobrane in the treatment of toxic epidermal necrolysis","volume":"16","author":"Kucan","year":"1995","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2009.06.213_bib99","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.burns.2007.06.008","article-title":"Toxic epidermal necrolysis: use of Biobrane\u00ae for skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients","volume":"34","author":"Boorboor","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.burns.2009.06.213_bib100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70196-0","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Wolkenstein","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.burns.2009.06.213_bib101","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1046\/j.1524-4725.2002.02119.x","article-title":"Skin allograft in the treatment of toxic epidermal necrolysis (TEN)","volume":"28","author":"Pianigiani","year":"2002","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.burns.2009.06.213_bib102","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1468-3083.2006.01919.x","article-title":"Lyell's syndrome skin lesions treated by Veloderm\u00ae","volume":"21","author":"Melandri","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.burns.2009.06.213_bib103","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.burns.2006.12.008","article-title":"AQUACEL\u00ae Ag in the treatment of toxic epidermal necrolysis (TEN)","volume":"34","author":"Huang","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.burns.2009.06.213_bib104","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.burns.2009.06.213_bib106","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000248010","article-title":"Management of nonstaphylococcal toxic epidermal necrolysis: follow-up study of 16 case histories","volume":"180","author":"Tegelberg-Stassen","year":"1990","journal-title":"Dermatologica"},{"key":"10.1016\/j.burns.2009.06.213_bib107","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2340\/0001555571171172","article-title":"Toxic epidermal necrolysis in patients receiving glucocorticosteroids","volume":"71","author":"Rzany","year":"1991","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.burns.2009.06.213_bib108","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1046\/j.1365-4362.1997.00100.x","article-title":"Toxic epidermal necrolysis\u2014a retrospective study","volume":"36","author":"Criton","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib109","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00004630-199711000-00009","article-title":"Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage","volume":"18","author":"Engelhardt","year":"1997","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2009.06.213_bib110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.burns.2009.06.213_bib111","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archderm.131.6.669","article-title":"Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy","volume":"131","author":"Guibal","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib112","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1525-1470.2002.00002.x","article-title":"Stevens\u2013Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy","volume":"19","author":"Samimi","year":"2002","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib113","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00007611-199610000-00015","article-title":"Cyclophosphamide in the treatment of toxic epidermal necrolysis","volume":"89","author":"Frangogiannis","year":"1996","journal-title":"South Med J"},{"key":"10.1016\/j.burns.2009.06.213_bib114","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1046\/j.1365-2133.1998.2576n.x","article-title":"Severe bullous drug reactions treated successfully with cyclophosphamide","volume":"139","author":"Trautmann","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Ar\u00e9valo","year":"2000","journal-title":"J Trauma"},{"key":"10.1016\/j.burns.2009.06.213_bib116","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2230.1997.tb01044.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor","volume":"22","author":"Jarrett","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib117","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.burns.2009.06.213_bib118","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (Infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib119","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib120","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.121.12.1548","article-title":"Plasmapheresis in severe drug-induced toxic epidermal necrolysis","volume":"121","author":"Kamanabroo","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib121","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib122","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","article-title":"Toxic epidermal necrolysis (Lyell syndrome)","volume":"23","author":"Roujeau","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib123","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/039139889101401006","article-title":"Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN)","volume":"14","author":"Sakellariou","year":"1991","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.burns.2009.06.213_bib124","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.burns.2009.06.213_bib125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2009.06.213_bib127","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis (TEN) and Stevens\u2013Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis","volume":"33","author":"Stella","year":"2007","journal-title":"Burns"},{"key":"10.1016\/j.burns.2009.06.213_bib128","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0305-4179(01)00005-5","article-title":"Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins","volume":"27","author":"Paquet","year":"2001","journal-title":"Burns"},{"key":"10.1016\/j.burns.2009.06.213_bib129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib130","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2009.06.213_bib131","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2009.06.213_bib132","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjps.2004.12.007","article-title":"Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report","volume":"58","author":"Lissia","year":"2005","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.burns.2009.06.213_bib133","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1744-9987.2008.00609.x","article-title":"Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan","volume":"12","author":"Yamada","year":"2008","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.burns.2009.06.213_bib134","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000131753","article-title":"Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses","volume":"10","author":"Michael","year":"2008","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.burns.2009.06.213_bib135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0305-4179(01)00102-4","article-title":"The use of a PEG tube in a burn centre","volume":"28","author":"Kreis","year":"2002","journal-title":"Burns"}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417909003945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417909003945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T17:54:20Z","timestamp":1710611660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417909003945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0305417909003945"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2009.06.213","relation":{},"ISSN":["0305-4179"],"issn-type":[{"value":"0305-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}